ADALIMUMAB SERUM DRUG LEVELS AND ANTI-DRUG ANTIBODIES: ASSOCIATION TO DISEASE ACTIVITY AND DRUG SURVIVAL IN INFLAMMATORY ARTHRITIS PATIENTS

被引：0

作者：

Jyssum, I. ^{[1
,2
]}

Gehin, J. E. ^{[3
]}

Kristianslund, E. ^{[1
]}

Sexton, J. ^{[1
]}

Worren, D. ^{[3
]}

Hu, Y. ^{[4
]}

Kvien, T. K. ^{[1
]}

Haavardsholm, E. A. ^{[1
,2
]}

Bolstad, N. ^{[3
]}

Syversen, S. W. ^{[1
]}

Goll, G. L. ^{[1
]}

机构：

[1] Diakonhjemmet Hosp, Ctr treatment Rheumat & Musculoskeletal Dis REMED, Oslo, Norway

[2] Univ Oslo, Inst Clin Med, Oslo, Norway

[3] Norwegian Radium Hosp, Dept Med Biochem, Oslo, Norway

[4] Lillehammer Hosp, Dept Rheumatol, Lillehammer, Norway

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷

关键词：

Inflammatory arthritides; bDMARD;

D O I：

10.1136/annrheumdis-2023-eular.1369

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

POS0345

引用

页码：421 / 422

页数：2

共 50 条

[1] Adalimumab serum levels and anti -drug antibodies: association to treatment response and drug survival in inflammatory arthritis patients
Jyssum, I.
Gehin, J.
Sexton, J.
Kristianslund, E.
Hu, Y.
Warren, D.
Kvien, T.
Haavardsholm, E.
Syversen, S.
Bolstad, N.
Goll, G.
[J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2023, 52 : 34 - 36
[2] DIFFERENCES IN SERUM DRUG LEVELS AND ANTI-DRUG ANTIBODIES IN PATIENTS WITH INFLAMMATORY ARTHRITIS TREATED WITH ORIGINATOR VS BIOSIMILAR ADALIMUMAB
Jyssum, I.
Gehin, J. E.
Kristianslund, E.
Sexton, J.
Worren, D.
Hu, Y.
Kvien, T. K.
Haavardsholm, E. A.
Bolstad, N.
Syversen, S. W.
Goll, G. L.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 362 - 363
[3] Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases
Jyssum, Ingrid
Gehin, Johanna E.
Sexton, Joseph
Kristianslund, Eirik Klami
Hu, Yi
Warren, David John
Kvien, Tore K.
Haavardsholm, Espen A.
Syversen, Silje Watterdal
Bolstad, Nils
Goll, Guro Lovik
[J]. RHEUMATOLOGY, 2024, 63 (06) : 1746 - 1755
[4] Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease
Strik, A. S.
van den Brink, G. R.
Ponsioen, C.
Mathot, R.
Loewenberg, M.
D'Haens, G. R.
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 (08) : 1128 - 1134
[5] Measurement of Anti-TNF Agents and Anti-Drug Antibodies Serum Levels in Patients with Inflammatory Bowel Disease
Guerra, Ivan
Chaparro, Maria
Bermejo, Fernando
Gisbert, Javier P.
[J]. CURRENT DRUG METABOLISM, 2014, 15 (09) : 875 - 881
[6] Relationship Between Adalimumab Concentrations, Plasma Cytokines, Anti-drug Antibodies and Disease Activity in Rheumatoid Arthritis
Stamp, Lisa
Keating, Paula
Frampton, Christopher
Barclay, Murray
Fanning, Niamh
Millier, Melanie
Hessian, Paul
O'Donnell, John
[J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
[7] Disappearance of anti-drug antibodies to infliximab and adalimumab after addition of an immunomodulator in patients with inflammatory bowel disease
Strik, A.
van den Brink, G.
Ponsioen, C.
Mathot, R.
Lowenberg, M.
D'Haens, G.
[J]. JOURNAL OF CROHNS & COLITIS, 2016, 10 : S69 - S70
[8] Should anti-TNF-α drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis?
Mulleman, Denis
Ducourau, Emilie
Paintaud, Gilles
Ternant, David
Watier, Herve
Goupille, Philippe
[J]. JOINT BONE SPINE, 2012, 79 (02) : 109 - 112
[9] Adalimumab Serum Concentrations or Anti-Drug Antibodies Do Not Influence Fatigue in Patients with Crohn's Disease
Karlsen, Lars Normann
Carlsen, Arne
Omdal, Roald
Aabakken, Lars
Bolstad, Nils
Lundin, Knut
Grimstad, Tore
[J]. INFLAMMATORY BOWEL DISEASES, 2017, 23 : S44 - S45
[10] Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels
Jani, Meghna
Isaacs, John D.
Morgan, Ann W.
Wilson, Anthony G.
Plant, Darren
Hyrich, Kimme L.
Chinoy, Hector
Barton, Anne
[J]. RHEUMATOLOGY, 2016, 55 (11) : 2050 - 2055

← 1 2 3 4 5 →